The only pharmacovigilance platform built for payers. Real-time CNSS signal detection, ISPOR-compliant HEOR evidence, and AMCP Format 5.0 dossiers — generated in 60 seconds from your FHIR R4 endpoint.
Every tool in this space — Certara, IQVIA, Evidera — was built to help drug manufacturers submit evidence to you. PayerSignal generates that evidence from your own data, independently.
Traditional pharmacovigilance tools generate HEOR models that pharma submits in AMCP dossiers. Payers receive the output. They don't own the analysis, the data, or the assumptions.
FDA FAERS signals are real but they can't tell you that your semaglutide population has a pancreatitis NNH of 133 — 47% worse than the published benchmark. Only your claims data can.
A Certara HEOR model takes 6–12 months and costs $200K–$500K. Your P&T committee meets quarterly. PayerSignal generates NNH, BIA, and AMCP dossier in under 60 seconds.
Point PayerSignal at your FHIR R4 endpoint. OAuth2 client credentials, GCP Secret Manager. 15-minute IT integration.
PayerSignal extracts MedicationRequest + Condition resources, computes CNSS scores fused with FAERS PRR and literature signal strength.
NNH with 95% CI, Monte Carlo PSA, budget impact analysis, ICER benchmark alignment, NICE TA comparison. ISPOR-compliant, JMCP-publishable.
AMCP Format 5.0 dossier, PA criteria update, step therapy protocol, natural language P&T memo — all generated by Claude Sonnet 4.
Three-source signal fusion: plan claims (CNSS), FDA FAERS (PRR + chi-squared), and PubMed literature signal count. Weighted 50/30/20. Computes in 2ms per drug-ADE pair.
10,000-iteration Monte Carlo simulation across all uncertain parameters. Gamma distributions for costs, Beta for rates, Normal for utilities. Tornado diagram, CEAC at 21 WTP thresholds, NMB at $50K/$100K/$150K. JMCP-publishable under your plan's name.
Semaglutide at $182K/QALY per ICER 2024 obesity report — above $150K threshold. Value-based price $9,930/yr vs WAC $12,048/yr. NICE TA875. Published NNH benchmarks from Prime Therapeutics. P&T committee minutes that cite independent third-party evidence.
Two-pass Claude Sonnet 4 architecture. Type "Which GLP-1 drugs have pancreatitis signals above MODERATE with EU corroboration?" and receive a P&T committee memo in 4 seconds. No SQL. No dashboards. No training required.
Without PayerSignal: "FLAG FOR REVIEW." With PayerSignal: "Semaglutide is T3-PA at UHG. Step therapy: metformin (90 days, HbA1c ≥7.0%) → dulaglutide (90 days) → requested drug. PA criteria: lipase/amylase at baseline. Bypass criteria: documented pancreatitis history, MEN2, medullary thyroid carcinoma."
That's an operationally deployable PA protocol generated in under 1 second. Updated from live FHIR MedicationKnowledge resources. 15 payers pre-seeded.
Every HEOR output from PayerSignal follows ISPOR Good Practices, AMCP Format 5.0, and Drummond et al. methodology. A P&T pharmacist can submit the PSA output as a study to JMCP under the plan's name.
That publication is the reference case that brings in the next 10 payers.
No new data warehouse. No SFTP extracts. Connect via FHIR R4 in 15 minutes. Deploy on GCP in one command.
We'll connect to your FHIR R4 endpoint, run PayerSignal against your actual population, and show you your NNH, burden, and ICER benchmark in a live 30-minute session.